To further address the effects of ubiquitination-devoid ATF3 mutations on p53 activity in cancer, we subjected several missense mutations in the region flanking the MDM2-binding sites or the ubiquitination sites for in vitro ubiquitination assays. The gene discussed is MDM2; the disease is cancer.